(Q46798255)

English

A fludarabine, thiotepa reduced toxicity conditioning regimen designed specifically for allogeneic second haematopoietic cell transplantation after failure of previous autologous or allogeneic transplantation

scientific article published on 21 January 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18209719

A fludarabine, thiotepa reduced toxicity conditioning regimen designed specifically for allogeneic second haematopoietic cell transplantation after failure of previous autologous or allogeneic transplantation (English)

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18209719

author name string

C Grüllich

1

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18209719

H Bertz

2

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18209719

A Spyridonidis

3

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18209719

C I Müller

4

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18209719

J Finke

5

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18209719

language of work or name

0 references

publication date

21 January 2008

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18209719

Bone Marrow Transplantation

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18209719

41

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18209719

10

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18209719

845-850

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18209719

https://scigraph.springernature.com/pub.10.1038/sj.bmt.1705989

0 references

Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705989

21 January 2018

Allografting after nonmyeloablative conditioning as a treatment after a failed conventional hematopoietic cell transplant

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705989

21 January 2018

Effect of age and previous autologous transplantation on nonrelapse mortality and survival in patients treated with reduced-intensity conditioning and allografting for advanced hematologic malignancies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705989

21 January 2018

Allogeneic bone marrow transplantation in patients who relapse after autologous transplantation.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705989

21 January 2018

Treatment of leukemia by alloreactive lymphocytes and nonmyeloablative stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705989

21 January 2018

Non-myeloablative allografting from human leucocyte antigen-identical sibling donors for treatment of acute myeloid leukaemia in first complete remission

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705989

21 January 2018

Reduced intensity conditioning: enhanced graft-versus-tumor effect following dose-reduced conditioning and allogeneic transplantation for refractory lymphoid malignancies after high-dose therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705989

21 January 2018

Nonmyeloablative stem cell transplantation for the treatment of cancer and life-threatening nonmalignant disorders: past accomplishments and future goals

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705989

21 January 2018

Reduced-intensity conditioning regimen with thiotepa and fludarabine followed by allogeneic blood stem cell transplantation in haematological malignancies.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705989

21 January 2018

Allogeneic Stem-Cell Transplantation From Related and Unrelated Donors in Older Patients With Myeloid Leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705989

21 January 2018

Cellular and clinical pharmacology of fludarabine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705989

21 January 2018

Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705989

21 January 2018

The dismal outcome in patients with acute leukaemia who relapse after an autograft is improved if a second autograft or a matched allograft is performed. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705989

7 January 2021

based on heuristic

inferred from DOI database lookup

Second allogeneic marrow transplantation for patients with recurrent leukemia after initial transplant with total-body irradiation-containing regimens

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705989

7 January 2021

based on heuristic

inferred from DOI database lookup

Allogeneic marrow transplantation for patients with acute non-lymphoblastic leukemia in second remission

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705989

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase I-II study of cyclophosphamide, thiotepa, and carboplatin with autologous bone marrow transplantation in solid tumor patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705989

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705989

7 January 2021

based on heuristic

inferred from DOI database lookup

Matched and mismatched allogeneic stem-cell transplantation from unrelated donors using combined graft-versus-host disease prophylaxis including rabbit anti-T lymphocyte globulin

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705989

7 January 2021

based on heuristic

inferred from DOI database lookup

Acute and chronic graft-versus-host disease in man.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705989

7 January 2021

based on heuristic

inferred from DOI database lookup

Immunosuppression with limited toxicity: the characteristics of nucleoside analogs and anti-lymphocyte antibodies used in non-myeloablative hematopoietic cell transplantation.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705989

7 January 2021

based on heuristic

inferred from DOI database lookup

The role of thiotepa in allogeneic stem cell transplantation in patients with leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705989

7 January 2021

based on heuristic

inferred from DOI database lookup

Impact of previous high-dose therapy on outcome after allografting for multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705989

7 January 2021

based on heuristic

inferred from DOI database lookup

Allogeneic Stem Cell Transplantation in First Complete Remission Enhances Graft-versus-Leukemia Effect in Adults with Acute Lymphoblastic Leukemia: Antileukemic Activity of Chronic Graft-versus-Host Disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705989

7 January 2021

based on heuristic

inferred from DOI database lookup

Hematopoietic cell transplantation from unrelated donors as an effective therapy for older patients (> or = 60 years) with active myeloid malignancies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705989

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/SJ.BMT.1705989

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18209719

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18209719

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46798255&oldid=2144916803"